Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged
non-small-cell lung cancer (NSCLC) is not known. We assessed the …

… a randomised, open-label phase 3 … randomly assigned (1:1) patients to oral sotorasib (960
mg once daily) or intravenous docetaxel (75 mg/m 2 once every 3 weeks) in an open-label …

… randomised, open-label, phase 3 study at 47 institutions in Japan. Patients with extensive-disease
small-cell lung cancer … and no brain metastases on MRI were randomly assigned (1:1) …

Background First-line pembrolizumab monotherapy improves overall and progression-free
survival in patients with untreated metastatic non-small-cell lung cancer with a programmed …

… In this non-randomised, open-label, phase 2 trial, we enrolled patients aged 18 years or
older with melanoma or NSCLC with untreated brain metastases from the Yale Cancer Center. …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …

Background Immunotherapy with PD-1 or PD-L1 blockade fails to induce a response in about
80% of patients with unselected non-small cell lung cancer (NSCLC), and many of those …

Background Icotinib has provided survival benefits for patients with advanced, epidermal
growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to …

… Lung cancer is the leading cause of cancer-related mortality worldwide, and non-small-cell
lung cancer (NSCLC) is the most common form, accounting for ∼85% of all cases. Five-year …

… or carcinoid lung cancer; atypical EGFR mutations; history of brain or leptomeningeal
metastases; history of, or currently suspected, diffuse non-infectious pneumonitis or interstitial lung …